SleepWell24, a Smartphone Application to Promote Adherence to Positive Airway Pressure Therapy: Feasibility and Acceptability in a Randomized Controlled Trial

To investigate the feasibility and acceptability of SleepWell24, a multicomponent, evidence-based smartphone application, to improve positive airway pressure therapy (PAP) adherence, among patients with obstructive sleep apnea (OSA) naive to PAP. In a single-blind randomized controlled trial, SleepW...

Full description

Saved in:
Bibliographic Details
Published in:Behavioral sleep medicine 2024-07, Vol.22 (4), p.420-432
Main Authors: Petrov, Megan E., Epstein, Dana R., Krahn, Lois, Todd, Michael, Park, John G., St. Louis, Erik K., Morgenthaler, Timothy I., Hoffmann, Coles M., Hasanaj, Kristina, Hollingshead, Kevin, Yu, Tsung-Yen, Buman, Matthew P.
Format: Article
Language:English
Subjects:
Adherence
Behavior modification
Chronic illnesses
Circadian rhythm
Clinical outcomes
Clinical research
Clinical trials
Disease management
Feasibility
Obstructive sleep apnea
Physical activity
Recruitment
Retention
Sleep apnea
Smartphones
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the feasibility and acceptability of SleepWell24, a multicomponent, evidence-based smartphone application, to improve positive airway pressure therapy (PAP) adherence, among patients with obstructive sleep apnea (OSA) naive to PAP. In a single-blind randomized controlled trial, SleepWell24, with a companion activity monitor was compared to usual care plus the activity monitor and its associated app. SleepWell24 provides objective feedback on PAP usage and sleep/physical activity patterns, and chronic disease management. Patients were recruited from two sleep medicine centers and followed over the first 60 days of PAP. Feasibility and acceptability were measured by recruitment/retention rates, app usage, differences in post-trial Treatment Evaluation Questionnaire (TEQ) scores, and patient interviews. Exploratory, intent-to-treat logistic and linear mixed models estimated PAP adherence and clinical outcomes. Of 103 eligible participants, 87 were enrolled (SleepWell24 n = 40, control n = 47; mean 57.6y [SD = 12.3], 44.8% female). Retention was ≥95% across arms. There were no significant differences in TEQ scores. SleepWell24 participants engaged with the app on 62.9% of trial days. PAP use was high across both arms (SleepWell24 vs. Control: mean hours 5.98 vs. 5.86). There were no differences in PAP adherence or clinical outcomes. SleepWell24 was feasible and acceptable among PAP-naive patients with OSA. NCT03156283 https://www.clinicaltrials.gov/study/NCT03156283
ISSN:1540-2002
1540-2010
1540-2010
DOI:10.1080/15402002.2023.2289442